My (limited) understanding is that the high costs are, in many cases, largely a matter of overhead and regulatory compliance, not technical or technological.
If that’s the case, understanding the costs could allow reform of the regulations to reduce the costs and make clinical trials cheaper.
My (limited) understanding is that the high costs are, in many cases, largely a matter of overhead and regulatory compliance, not technical or technological.
If that’s the case, understanding the costs could allow reform of the regulations to reduce the costs and make clinical trials cheaper.